Derbes, VJ. De Mussis and the great plague of 1348. A forgotten episode of bacteriological warfare. JAMA April 4, 1966; 196(1): 59–62.CrossRefGoogle ScholarPubMed

Parkman, F. The Conspiracy of Pontiac and the Indian War after the Conquest of Canada. vol. 2. Boston MA, Little, Brown, and Co, 1901.Google Scholar

Koenig, R. The Fourth Horseman: One man's secret campaign to fight the Great War in America. New York: Public Affairs, 2006.Google Scholar

Hugh-Jones, M. Wickham Steed and German biological warfare research. Intell Natl Secur 1992; 7: 379–402.Google Scholar

Harris, S. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci December 31, 1992; 666: 21–52.CrossRefGoogle ScholarPubMed

Christopher, GW, Cieslak, TJ, Pavlin, JA, Eitzen EM, Jr. Biological warfare. A historical perspective. JAMA August 6, 1997; 278(5): 412–417.CrossRefGoogle ScholarPubMed

Carus, W. Bioterrorism and biocrimes: the illicit use of biological agents in the 20th century. Washington, DC, National Defense University, 1999.Google Scholar

Protocol for the Prohibition of the Use in War of Asphyxiat-ing, Poisonous or Other Gases, and of Bacteriological Methods of Warfare. Signed at Geneva June 17, 1925. http://www.un.org/disarmament/WMD/Bio/pdf/Status_Protocol.pdf (Accessed August 27, 2015).Google Scholar

Sims, N. The diplomacy of biological disarmament. vol. 18. New York, St Martin's Press, 1988.Google Scholar

UDot, Army. US Army activity in the US biological warfare programs. Washington, DC, U.S. Dept of the Army, February 24, 1977; 2.Google Scholar

Vorobjev, A, Cherkassky, B, Stepanov, A, Kyuregyan, Y, Fjedorov, M. Key problems of controlling especially dangerous infections. Paper presented at: Proceedings of an International Symposium: Severe infection diseases: epidemiology, express-diagnostics and prevention. Kirov, Russia, 1997.Google Scholar

Alibek, K, Handelman, S. Biohazard : the chilling true story of the largest covert biological weapons program in the world, told from the inside by the man who ran it. 1st ed. New York, Random House, 1999.Google Scholar

Torok, TJ, Tauxe, RV, Wise, RP, et al. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA August 6, 1997; 278(5): 389–395.CrossRefGoogle ScholarPubMed

Kolavic, SA, Kimura, A, Simons, SL, Slutsker, L, Barth, S, Haley, CE. An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination. JAMA August 6, 1997; 278(5): 396–398.CrossRefGoogle ScholarPubMed

Jernigan, DB, Raghunathan, PL, Bell, BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis October 2002; 8(10): 1019–1028.CrossRefGoogle Scholar

7 CFR Part 331, 9 CFR Part 121, 42 CFR Part 73.Google Scholar

Atlas, R. Biological weapons pose challenge for microbiology community. ASM News 1998; 64: 383–389.Google Scholar

NATO Handbook on the Medical Aspects of NBC Defensive Operations (AmedP-6) Departments of the Army, Navy, and Air Force, February 1996. http://fas.org/irp/doddir/army/fm8-9.pdfGoogle Scholar

Joshi, D, Kumar, D, Maini, AK, Sharma, RC. Detection of biological warfare agents using ultra violet-laser induced fluorescence LIDAR. Spectrochim Acta A Mol Biomol Spectrosc August 2013; 112: 446–456.CrossRefGoogle Scholar

Bioterrorism alleging use of anthrax and interim guidelines for management – United States, 1998. MMWR, February 5, 1999; 48(4): 69–92.Google Scholar

Health aspects of chemical and biological weapons. Geneva, World Health Organization, 1970.Google Scholar

Rotz, LD, Khan, AS, Lillibridge, SR, Ostroff, SM, Hughes, JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis February 2002; 8(2): 225–230.CrossRefGoogle ScholarPubMed

CDC. Inhalation anthrax associated with dried animal hides – Pennsylvania and New York City, 2006. MMWR 2006; 55(10): 280–282.Google Scholar

CDC. Cutaneous anthrax associated with drum making using goat hides from West Africa – Connecticut, 2007. MMWR 2008; 57(23): 628–631.Google Scholar

Jernigan, JA, Stephens, DS, Ashford, DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis November–December 2001; 7(6): 933–944.CrossRefGoogle ScholarPubMed

Sprenkle, MD, Griffith, J, Marinelli, W, Boyer, AE, Quinn CP, Pesik NT, et al. Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA. Emerg Infect Dis February 2014. http://dx.doi.org/10.3201/eid2002.130245 (Accessed March 13, 2014).CrossRefGoogle Scholar

Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. MMWR Morb Mortal Wkly Rep 2001; 50(43): 960.Google Scholar

CDC. Use of vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2010; 59(RR-6): 1–30.Google Scholar

CDC. Use of vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2010; 59(RR-6): 1–30.Google Scholar

Stern, EJ, Uhde, KB, Shadomy, SV, Messonnier, N. Conference report on public health and clinical guidelines for anthrax [conference summary]. Emerg Infect Dis April 2008. http://wwwnc.cdc.gov/eid/article/14/4/07–0969.htm (Accessed September 9, 2013).CrossRefGoogle ScholarPubMed

Inglesby, TV, O'Toole, T, Henderson, DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA May 1, 2002; 287(17): 2236–2252.CrossRefGoogle ScholarPubMed

Department of Health and Human Services. Biological Products; Bacterial Vaccines and Toxoids; Implementation of Efficacy Review; Anthrax Vaccine Adsorbed; Final Order. Federal Register 2005; 70(242): 75180–75198.Google Scholar

Biothrax^TM (Anthrax Vaccine Absorbed). Prescribing information. Emergent Biosolutions, Rockville, MD. Revised May 2012. http://www.biothrax.com/prescribinginformation_biothrax_us.pdf (Accessed August 27, 2015).Google Scholar

Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2002; 51(45): 1024–1026.Google Scholar

Fenner, FHD, Arita, I, Jezek, Z, Ladnyi, ID. Smallpox and its eradication. Geneva, World Health Organization, 1988.Google Scholar

Henderson, DA, Inglesby, TV, Bartlett, JG, et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA June 9, 1999; 281(22): 2127–2137.CrossRefGoogle Scholar

Smith, JA, Casey, CG, Tierney, BC. The ocular complications of smallpox and smallpox immunization. Arch Ophthalmol September 2004; 122(9): 1407; author reply 1407–1408.CrossRefGoogle ScholarPubMed

Eeckels, R, Vincent, J, Seynhaeve, V. Bone Lesions Due to Smallpox. Arch Dis Child December 1964; 39: 591–597.CrossRefGoogle ScholarPubMed

Wehrle, PF, Posch, J, Richter, KH, Henderson, DA. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ 1970; 43(5): 669–679.Google Scholar

Jezek, Z, Szczeniowski, M, Paluku, KM, Mutombo, M. Human monkeypox: clinical features of 282 patients. J Infect Dis August 1987; 156(2): 293–298.CrossRefGoogle ScholarPubMed

Update: multistate outbreak of monkeypox – Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003. MMWR Morb Mortal Wkly Rep July 11, 2003; 52(27): 642–646.Google Scholar

http://www.cdc.gov/ncidod/monkeypox/vaccineqa.htm (Accessed August 27, 2015).Google Scholar

Buller, RM, Owens, G, Schriewer, J, Melman, L, Beadle, JR, Hostetler, KY. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology January 20, 2004; 318(2): 474–481.CrossRefGoogle Scholar

Acute, Generalized Vesicular or Pustular Rash Illness Testing Protocol in the United States. Centers for Disease Control and Prevention, Atlanta, GA, 2006. http://www.bt.cdc.gov/agent/smallpox/diagnosis/rashtestingprotocol-chart2.asp (Accessed August 27, 2015).Google Scholar

Beachkofsky, TM, Carrizales, SC, Bidinger, JJ, Hrncir, DD, Whitemore, DE, Hivnor, CM. Adverse events following smallpox vaccination with ACAM2000 in a military population. Arch Dermatol 2010; 146(6): 656–661.CrossRefGoogle Scholar

Smallpox Vaccine. Dried, Calf Lymph Type. Dryvax. Dried Smallpox Vaccine. Package Insert. Philadelphia, Wyeth Pharmaceuticals, Inc., June 2007.Google Scholar

Casey, CG, Iskander, JK, Roper, MH, et al. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA December 7, 2005; 294(21): 2734–2743.CrossRefGoogle ScholarPubMed

Smallpox vaccination and adverse reactions: guidance for clinicians. Ann Pharmacother March 2003; 37(3): 467–468.CrossRefGoogle Scholar

Grabenstein, JD, Winkenwerder, W. US military smallpox vaccination program experience. JAMA June 25, 2003; 289(24): 3278–3282.CrossRefGoogle ScholarPubMed

Centers for Disease Control and Prevention. Supplemental recommendations on adverse events following smallpox vaccine in the pre-event vaccination program: recommendations of the Advisory Committee on Immunization Practices. JAMA April 23–30, 2003; 289(16): 2064.CrossRefGoogle Scholar

Parrino, J, Graham, BS. Smallpox vaccines: Past, present, and future. J Allergy Clin Immunol December 2006; 118(6): 1320–1326.CrossRefGoogle ScholarPubMed

Wittek, R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis May 2006; 10(3): 193–201.CrossRefGoogle ScholarPubMed

Inglesby, TV, Dennis, DT, Henderson, DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA May 3, 2000; 283(17): 2281–2290.Google ScholarPubMed

Dembek, ZF, et al., eds. Medical Management of Biological Casualties Handbook. The USAMRIID “Blue Book.” 7th ed. Fort Detrick, MD, USAMRIID, September 2011.Google Scholar

Perry, RD, Fetherston, JD. Yersinia pestis–etiologic agent of plague. Clin Microbiol Rev January 1997; 10(1): 35–66.CrossRefGoogle ScholarPubMed

Sonnabend, O, Sonnabend, W, Heinzle, R, Sigrist, T, Dirnhofer, R, Krech, U. Isolation of Clostridium botulinum type G and identification of type G botulinal toxin in humans: report of five sudden unexpected deaths. J Infect Dis January 1981; 143(1): 22–27.CrossRefGoogle ScholarPubMed

Barash, JR, Tang, TW, Arnon, SS. First case of infant botulism caused by Clostridium baratii type F in California. J Clin Microbiol August 2005; 43(8): 4280–4282.CrossRefGoogle ScholarPubMed

Aureli, P, Fenicia, L, Pasolini, B, Gianfranceschi, M, McCroskey, LM, Hatheway, CL. Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy. J Infect Dis August 1986; 154(2): 207–211.CrossRefGoogle ScholarPubMed

Passaro, DJ, Werner, SB, McGee, J, Mac Kenzie, WR, Vugia, DJ. Wound botulism associated with black tar heroin among injecting drug users. JAMA March 18, 1998; 279(11): 859–863.CrossRefGoogle ScholarPubMed

Spika, JS, Shaffer, N, Hargrett-Bean, N, Collin, S, MacDonald, KL, Blake, PA. Risk factors for infant botulism in the United States. Am J Dis Child July 1989; 143(7): 828–832.Google ScholarPubMed

Arnon, SS, Schechter, R, Maslanka, SE, Jewell, NP, Hatheway, CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med February 2, 2006; 354(5): 462–471.CrossRefGoogle ScholarPubMed

Borio, L, Inglesby, T, Peters, CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287: 2391–2405.CrossRefGoogle ScholarPubMed

Snell, NJ. Ribavirin–current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001; 2: 1317–1324.CrossRefGoogle ScholarPubMed

Rusnak, JM H., Byrne, WR, Chung, KN, et al. Experience with ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res January 2009; 81(1): 68–76.CrossRefGoogle ScholarPubMed

Mertz, GJ, Miedzinski, L, Goade, D, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004; 39: 1307–1313.CrossRefGoogle ScholarPubMed

Gowen, BB, Bray, M. Progress in the experimental therapy of severe arenaviral infections. Future Microbiol December 2011; 6(12): 1429–1441.CrossRefGoogle ScholarPubMed

McCormick, JB, King, I, Webb, P, et al. Lassa fever: Effective therapy with Ribavirin. N Engl J Med 1986; 314: 20–26.CrossRefGoogle ScholarPubMed

Cetron, MS, Marfin, AA, Julian, KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2002; 51(RR-17): 1–11.Google ScholarPubMed

Dennis, DT, Inglesby, TV, Henderson, DA, et al. Tularemia as a biological weapon, medical and public health management. JAMA 2001; 285: 2763–2773.CrossRefGoogle ScholarPubMed

Rogozin, II. Tularemia prevention during the Second World War. Zh Mikrobiol Epidemiol Immunobiol 1970; 47: 23–26.Google ScholarPubMed

Croddy, E, Krcalova, S. Tularemia, biological warfare, and the battle for Stalingrad (1942–1943). Mil Med 2001; 166: 837–838.CrossRefGoogle ScholarPubMed

Alibek, K. Biohazard. New York, Random House, 1999; 29–38.Google Scholar

Feldman, KA, Enscore, RE, Lathrop, SL, et al. An outbreak of primary pneumonic tularemia on Martha's Vineyard. New Engl J Med 2001; 345: 1601–1606.CrossRefGoogle ScholarPubMed

Feldman, KA, Stiles-Enos, D, Julian, K, et al. Tularemia on Martha's Vineyard: Seroprevalence and occupational risk. Emerg Infect Dis 2003; 9: 350–354.CrossRefGoogle ScholarPubMed

Rusnak, JM, Kortepeter, MG, Hawley, RJ, et al. Risk of occupationally acquired illnesses from biological threat agents in unvaccinated laboratory workers. Biosecur Bioterror 2004; 2: 281–293.CrossRefGoogle ScholarPubMed

Enderlin, G, Morales, L, Jacobs, RF, Cross, JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994; 19: 42–47.CrossRefGoogle ScholarPubMed

Marohn, ME, Barry, EM. Live attenuated tularemia vaccines: Recent developments and future goals. Vaccine 2013; 31: 3485–3491.CrossRefGoogle ScholarPubMed

4th July, 1817, 42d year. [Bennington]. Vermont Gazette. July 8, 1817; 2: “let your motto be ‘eternal vigilance is the price we pay for liberty.’”Google Scholar